Tuberculosis progression rates in U.S. Immigrants following screening with interferon-gamma release assays

BMC Public Health

Table 3 Incident active TB cases

Case	IGRA	Ag-Nil, Mitogen (IU/ml)	CXR findings	HIV	Diabetes	Smoker	TB Class	Treatment status^a	TB confirmation
1	Neg	0.38–0.11, 20	Pleural thickening, RUL	Neg	No	No	B1	None	Lung biopsy pathology
2	Pos	0.93–0.12, 2.0	Fibronodular changes, BUL & LLL	Unk	No	No	B2	None	sputum culture
3	Neg	0.29–0.11, 25	Fibrotic changes, LUL	Neg	No	No	B2	Incomplete tx prior to immigration^b	sputum culture
4	Pos	2.4–0.12, 25	Fibronodular changes, RUL	Neg	No	No	B1	LTBI tx at enrollment	sputum culture
5	Pos	9.7–0.70, 24	Normal	Neg	No	No	B1	LTBI tx at enrollment	sputum culture
6	Pos	3.1–0.12, 8.9	Nodular infiltrate, LUL	Neg	No	No	B1	LTBI tx at enrollment	sputum culture
7	Pos	1.1–0.16, 6.9	Fibrotic changes, LUL; Effusion, L	Neg	No	No	B1	Incomplete LTBI tx at enrollment^c	sputum culture

Abbreviations: TB tuberculosis, IGRA interferon-gamma release assay, Ag-Nil interferon-gamma response with antigen minus response without antigen, Mitogen interferon-gamma response to mitogen, HIV human immunodeficiency virus, CXR chest x-ray, Pos positive, Neg negative, Unk unknown, RUL right upper lobe, BUL bilateral upper lobes, LLL left lower lobe, LUL left upper lobe, L left, LTBI latent tuberculosis infection, tx treatment
^aTreatment status reflects any TB treatment received up until the time of diagnosis with active TB disease: either overseas treatment for TB infection or disease prior to U.S. entry, or LTBI treatment received in the U.S. after immigration
^bDefaulted after 3 months of active TB treatment
^cReceived a 1 month prescription for isoniazid but was lost to follow-up. Unclear if patient took any of the medication

ISSN: 1471-2458